Keyword: Moderna Therapeutics
The candidate is designed to induce production of relaxin, a hormone seen as a way to regulate the conditions that exacerbate heart failure.
Gilead boosted oncology chief Riva to EVP, Moderna lost three top R&D officials, Bayer poached Pfizer's consumer marketing vet and more.
A back-loaded deal with CureVac moves Lilly into an emerging field that seeks to use mRNA to guide immune attacks on tumors.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.
The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.
Biogen poached a Pfizer medicinal sciences executive, AstraZeneca made two new oncology hires, Moderna tapped an industry veteran to oversee manufacturing.
The rejig sees Alexion scrapping deals with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma as it seeks to focus its R&D.
Evelo Biosciences has raised $50 million to take its monoclonal microbials into the clinic.
PPD has expanded its vaccine sciences lab in Richmond, Virginia, by another 17,000 square feet and added vaccine efficacy testing capacity using cell-based assays and immunochemistry.
CureVac has hired Daniel Menichella as CEO of its Boston-based subsidiary and tasked him with striking deals.